 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 0 | 1 | 1 | | 1987 | 0 | 1 | 1 | | 1990 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 2 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 3 | 3 | | 2010 | 3 | 0 | 3 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 1 | 3 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 2 | 4 | | 2017 | 5 | 1 | 6 | | 2018 | 2 | 2 | 4 | | 2019 | 3 | 1 | 4 | | 2020 | 0 | 1 | 1 | | 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Roehle K, Qiang L, Ventre KS, Heid D, Ali LR, Lenehan P, Heckler M, Crowley SJ, Stump CT, Ro G, Godicelj A, Bhuiyan AM, Yang A, Quiles Del Rey M, Biary T, Luoma AM, Bruck PT, Tegethoff JF, Nopper SL, Li J, Byrne KT, Pelletier M, Wucherpfennig KW, Stanger BZ, Akin JJ, Mancias JD, Agudo J, Dougan M, Dougan SK. cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci Transl Med. 2021 05 19; 13(594).
-
Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future Directions in the Treatment of Osteosarcoma. Cells. 2021 01 15; 10(1).
-
Tarhoni I, Wakefield CJ, Kollipara R, Fidler MJ, Batus M, Bonomi P, Borgia JA. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
-
Swindells S, Landay AL. Time to Study Immune Checkpoint Inhibitors in Patients With HIV Infection and Cancer. JCO Oncol Pract. 2020 06; 16(6):327-328.
-
Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, Guevara-Aleman G, Rossi M, Nowicki C, Abed A, Goldufsky JW, Broucek JR, Redondo RE, Rotter D, Jhawar SR, Wang SJ, Kohlhapp FJ, Kaufman HL, Thomas PG, Gupta V, Kuzel TM, Reiser J, Paras J, Kane MP, Singer EA, Malhotra J, Denzin LK, Sant'Angelo DB, Rabson AB, Lee LY, Lasfar A, Langenfeld J, Schenkel JM, Fidler MJ, Ruiz ES, Marzo AL, Rudra JS, Silk AW, Zloza A. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A. 2020 01 14; 117(2):1119-1128.
-
Vonk MM, Engen PA, Naqib A, Green SJ, Keshavarzian A, Blokhuis BRJ, Garssen J, Knippels LMJ, van Esch BCAM. Altered microbial community structure and metabolism in cow's milk allergic mice treated with oral immunotherapy and fructo-oligosaccharides. Benef Microbes. 2020 Feb 19; 11(1):19-32.
-
Landsburg DJ, Ayers EC, Bond DA, Maddocks KJ, Karmali R, Behdad A, Curry M, Wagner-Johnston ND, Modi D, Ramchandren R, Assouline SE, Faramand R, Chavez JC, Torka P, Mier Hicks A, Medeiros LJ, Li S. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol. 2020 04; 189(2):313-317.
-
Chatterjee D, Kordower JH. Immunotherapy in Parkinson's disease: Current status and future directions. Neurobiol Dis. 2019 12; 132:104587.
-
Sebio A, Wilky BA, Keedy VL, Jones RL. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211.
-
Ingram JR, Blomberg OS, Rashidian M, Ali L, Garforth S, Fedorov E, Fedorov AA, Bonanno JB, Le Gall C, Crowley S, Espinosa C, Biary T, Keliher EJ, Weissleder R, Almo SC, Dougan SK, Ploegh HL, Dougan M. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A. 2018 04 10; 115(15):3912-3917.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|